Anthem Biosciences Limited
(Formerly known as Anthem Biosciences Pvt. Ltd.)
49, F1 & F2, Canara Bank Road,
Bommasandra Industrial Area, Phase - I
Bommasandra. Bengaluru - 560 099
Karnataka, India
CIN : L24233KA2006PLC039703
Tel : + 91 80 6672 4000
www.anthembio.com

Date: November 03, 2026

To,

BSE Limited,
20th Floor, P.J. Towers,
Dalal Street,
Mumbai - 400001.
BSE Scrip Code: 544449

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051
NSE Scrip Symbol: ANTHEM

Subject: Earnings Call Presentation of the Company Pertaining to the quarter and half year ended September 30, 2026

Dear Sir/Ma'am

In continuation with the Company's letter dated October 30, 2026, pertaining to intimation of schedule of earnings call to be held on Wednesday, November 04, 2026, at 12:30 PM (IST) and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the earnings presentation on the Unaudited Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026.

The same is also available on the Company's website at https://anthembio.com/

We request you to kindly take the same on record.

Thanking you,

Yours truly,
For Anthem Biosciences Limited
(*Formerly known as Anthem Biosciences Private Limited*)

DIVYA PRASAD
Digitally signed by DIVYA PRASAD
Date: 2026.11.03 17:44:47 +05'30'

Divya Prasad
Company Secretary & Compliance Officer
Membership No: A41438

Anthem Biosciences Limited

Investor Presentation

November 3, 2026

Safe Harbour


Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute “forward-looking statements”. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.


Anthem® BioSciences


Consolidated Profit & Loss Statement: Q2FY27 vs Q2FY26 vs Q1FY27 Performance


Particulars (₹ Mn)	Q2FY27	Q2FY26	YoY	Q1FY27	QoQ	FY26
Revenue from Operations	**5,940**	**5,505**	***7.9%***	**4,182**	***42.0%***	**21,293**
CRDMO	5,093	4,662	*9.2%*	3,408	*49.4%*	17,775
Specialty Ingredients	848	843	*0.6%*	774	*9.5%*	3,518
Other Income	589	478	*23.3%*	249	*136.6%*	1,508
Total Revenues	**6,529**	**5,983**	*9.1%*	**4,431**	*47.4%*	**22,801**
Cost of materials consumed and changes in inventories	1,847	2,234	*-17.3%*	1,462	*26.3%*	8,123
Employee benefits expense	813	672	*20.9%*	788	*3.1%*	2,812
Other expenses	566	415	*36.2%*	426	*32.8%*	1,969
EBITDA	**3,304**	**2,661**	*24.1%*	**1,755**	*88.3%*	**9,896**
EBITDA Margins	***50.6%***	***44.5%***	*610 bps*	***39.6%***	*1,100 bps*	***43.4%***
Finance cost	33	31	*8.3%*	9	*273.0%*	71
Depreciation and amortization expense	307	335	*-8.3%*	300	*2.4%*	1,341
Profit before tax	**2,964**	**2,296**	*29.1%*	**1,446**	*105.0%*	**8,486**
Total tax expense	849	562	*51.2%*	246	*244.6%*	2,324
Profit after tax	**2,115**	**1,734**	*21.9%*	**1,199**	*76.3%*	**5,917**


Q2FY27 Consolidated Financial Highlights














Note:

1. EBITDA for Q2FY27 includes Other Income of INR 588.98 Mn (Other Operating Income o/a of forex gain (net) 57.54 Mn and Financial / Non Operating Income of INR 531.45 Mn). Corresponding figures for Q2FY26 was Other Income of INR 477.53 Mn (Other Operating Income o/a of forex gain (net) INR 303.40 Mn and Financial / Non Operating Income of INR 174.13 Mn)

Growth accelerated in Q2FY27, yielding robust financial performance and highest ever margins

Strong Business Performance

₹5,940 Mn
Q2FY27 Revenues

50.6%
Q2FY27 EBITDA Margin

32.4%
Q2FY27 PAT Margin

Robust Technology and Infrastructure

2,344 / 1,173
Employees / Scientific Staff

425KL
Custom Synthesis Capacity

142KL
Fermentation Capacity

Strong Returns and Balance Sheet

26.8%/50.3%
ROE / Q2FY27 Post Tax ROCE

1.55x
Q2FY27 Gross Fixed Assets Turnover

1.16x
Net Cash / Q2FY27 EBITDA*


*Based on Annualised EBITDA


Anthem® BioSciences


Consolidated Profit & Loss Statement: H1FY27 vs H1FY26 Performance


Particulars (₹ Mn)	H1FY27	H1FY26	YoY	FY26
Revenue from Operations	**10,123**	**10,914**	*-7.2%*	**21,293**
CRDMO	8,501	9,195	*-7.6%*	17,775
Specialty Ingredients	1,622	1,718	*-5.6%*	3,518
Other Income	838	699	*19.9%*	1,508
Total Revenues	**10,960**	**11,613**	*-5.6%*	**22,801**
Cost of materials consumed and changes in inventories	3,309	4,542	*-27.2%*	8,123
Employee benefits expense	1,601	1,391	*15.1%*	2,812
Other expenses	992	875	*13.4%*	1,969
EBITDA	**5,059**	**4,805**	*5.3%*	**9,896**
EBITDA Margins	***46.2%***	***41.4%***	*480 bps*	***43.4%***
Finance cost	42	47	*-11.0%*	71
Depreciation and amortization expense	607	599	*1.3%*	1,341
Profit before tax	**4,410**	**4,159**	*6.0%*	**8,486**
Total tax expense	1,096	1,066	*2.8%*	2,324
Profit after tax	**3,314**	**3,092**	*7.2%*	**5,917**


H1FY27 Consolidated Financial Highlights














Note:

2. EBITDA for H1FY27 includes Other Income of INR 837.87 Mn (Other Operating Income o/a of forex gain (net) 70.22 Mn and Financial / Non Operating Income of INR 767.65 Mn). Corresponding figures for H1FY26 was Other Income of INR 699.08 Mn (Other Operating Income o/a of forex gain (net) INR 340.39 Mn and Financial / Non Operating Income of INR 358.69 Mn)

Financial performance continues to remain strong with robust return profile for H1FY27

Strong Business Performance

₹10,123 Mn
H1FY27 Revenues

46.2%
H1FY27 EBITDA Margin

30.2%
H1FY27 PAT Margin

Platforms across discovery to commercialization

65.3%
Commercial Molecules Contribution to Revenues

15 + 9
Commercial + Late Stage (Phase III) Molecules

8.1%
R&D Services Contribution to Revenues

Strong Returns and Balance Sheet

21.0% / 39.3%
ROE / H1FY27 Post Tax ROCE

1.32x
H1FY27 Gross Fixed Assets Turnover

1.52x
Net Cash / H1FY27 EBITDA*

*Based on Annualised EBITDA

Anthem® BioSciences

Financial Highlights: Q2FY27 and H1FY27

Quarterly Performance:

- Consolidated Revenue from Operations was ₹5,940 Mn for the quarter
  - CRDMO business delivered ₹5,093 Mn revenues
  - Specialty Ingredients delivered ₹848 Mn revenues
- EBITDA was ₹3,304 Mn, with EBITDA margins at 50.6%
- PAT (Profit After Tax) was ₹2,115 Mn, with PAT margins at 32.4%

Half Year Performance:

- Consolidated Revenue from Operations was ₹10,123 Mn for the half year
  - CRDMO business delivered ₹8,501 Mn revenues
  - Specialty Ingredients delivered ₹1,622 Mn revenues
- EBITDA was ₹5,059 Mn, with EBITDA margins at 46.2%
- PAT (Profit After Tax) was ₹3,314 Mn, with PAT margins at 30.2%
- Net Cash position as of Sept 30, 2026, is ₹15,380 Mn

Message from Chairman, MD and CEO



AJAY BHARDWAJ
Chairman, MD & CEO

"We are pleased to report a robust performance for Q2FY27, driven by our CRDMO revenue stream. Underlying demand continues to remains strong and we are confident in our ability to sustain growth and create long-term value for all stakeholders

We expanded our EBITDA and PAT margins year-on-year. By maintaining strict discipline around cost efficiencies, yield optimization, and workforce productivity, we have further solidified our industry-leading margins, and are well-positioned to sustain this performance all year".



Thank You

Anthem Biosciences Limited

Unit I: No.49, F1 &F2, Canara Bank Road, Bommasandra Industrial Area Phase 1, Bommasandra, Bangalore, 560 099, India

Unit II: Plot No 276-P & 277-P, Survey No-20, Harohalli Industrial Area, Phase II, Near Bannikuppe Village, Kanakapura Taluk, Ramnagar District, Harohalli, Karnataka 562112, India

NeoAnthem Lifesciences Private Limited

Unit III: 313-P,314-P, 318-P, Harohalli Industrial Area, Phase II, Kanakapura Taluk, Ramnagar District, Harohalli, Karnataka, 562112, India

For further information please contact

investors.abl@anthembio.com or anthem@adfactorspr.com